Parallel Advisors’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.05M | Buy |
2,711
+463
| +21% | +$172K | 0.02% | 507 |
|
|
2026
Q1 | $658K | Sell |
2,248
-37
| -2% | -$12.2K | 0.01% | 624 |
|
|
2025
Q4 | $801K | Buy |
2,285
+67
| +3% | +$22.6K | 0.01% | 519 |
|
|
2025
Q3 | $717K | Sell |
2,218
-64
| -3% | -$19.9K | 0.01% | 536 |
|
|
2025
Q2 | $888K | Sell |
2,282
-503
| -18% | -$202K | 0.02% | 447 |
|
|
2025
Q1 | $1.21M | Buy |
2,785
+328
| +13% | +$132K | 0.03% | 352 |
|
|
2024
Q4 | $907K | Sell |
2,457
-1,357
| -36% | -$568K | 0.02% | 424 |
|
|
2024
Q3 | $1.98M | Sell |
3,814
-106
| -3% | -$56.6K | 0.05% | 250 |
|
|
2024
Q2 | $2.12M | Buy |
3,920
+339
| +9% | +$179K | 0.05% | 229 |
|
|
2024
Q1 | $1.86M | Buy |
3,581
+530
| +17% | +$264K | 0.05% | 243 |
|
|
2023
Q4 | $1.44M | Sell |
3,051
-98
| -3% | -$45.3K | 0.04% | 267 |
|
|
2023
Q3 | $1.37M | Sell |
3,149
-225
| -7% | -$102K | 0.05% | 250 |
|
|
2023
Q2 | $1.5M | Buy |
3,374
+265
| +9% | +$122K | 0.05% | 246 |
|
|
2023
Q1 | $1.43M | Sell |
3,109
-983
| -24% | -$468K | 0.05% | 247 |
|
|
2022
Q4 | $2.1M | Buy |
4,092
+309
| +8% | +$157K | 0.09% | 151 |
|
|
2022
Q3 | $1.72M | Buy |
3,783
+850
| +29% | +$407K | 0.08% | 164 |
|
|
2022
Q2 | $1.42M | Sell |
2,933
-53
| -2% | -$26.2K | 0.07% | 184 |
|
|
2022
Q1 | $1.5M | Buy |
2,986
+238
| +9% | +$109K | 0.06% | 209 |
|
|
2021
Q4 | $1.27M | Buy |
2,748
+247
| +10% | +$104K | 0.05% | 231 |
|
|
2021
Q3 | $933K | Buy |
2,501
+20
| +0.8% | +$7.6K | 0.04% | 267 |
|
|
2021
Q2 | $947K | Buy |
2,481
+31
| +1% | +$11.8K | 0.04% | 265 |
|
|
2021
Q1 | $880K | Sell |
2,450
-90
| -4% | -$28.9K | 0.04% | 251 |
|
|
2020
Q4 | $816K | Sell |
2,540
-193
| -7% | -$59.2K | 0.04% | 239 |
|
|
2020
Q3 | $734K | Sell |
2,733
-68
| -2% | -$18.3K | 0.05% | 234 |
|
|
2020
Q2 | $736K | Buy |
2,801
+48
| +2% | +$12.8K | 0.05% | 227 |
|
|
2020
Q1 | $624K | Sell |
2,753
-242
| -8% | -$65.9K | 0.05% | 205 |
|
|
2019
Q4 | $905K | Sell |
2,995
-72
| -2% | -$19.8K | 0.07% | 196 |
|
|
2019
Q3 | $736K | Sell |
3,067
-329
| -10% | -$90.1K | 0.06% | 210 |
|
|
2019
Q2 | $958K | Sell |
3,396
-46
| -1% | -$12.6K | 0.09% | 158 |
|
|
2019
Q1 | $988K | Buy |
3,442
+259
| +8% | +$74.9K | 0.11% | 137 |
|
|
2018
Q4 | $836K | Buy |
3,183
+220
| +7% | +$60.5K | 0.12% | 131 |
|
|
2018
Q3 | $812K | Buy |
2,963
+1,137
| +62% | +$295K | 0.1% | 155 |
|
|
2018
Q2 | $434K | Buy |
1,826
+61
| +3% | +$14.1K | 0.06% | 202 |
|
|
2018
Q1 | $388K | Sell |
1,765
-12
| -0.7% | -$2.82K | 0.06% | 207 |
|
|
2017
Q4 | $400K | Sell |
1,777
-2
| -0.1% | -$426 | 0.07% | 196 |
|
|
2017
Q3 | $389K | Sell |
1,779
-67
| -4% | -$12.8K | 0.07% | 199 |
|
|
2017
Q2 | $344K | Buy |
1,846
+28
| +2% | +$5.03K | 0.06% | 224 |
|
|
2017
Q1 | $327K | Buy |
1,818
+352
| +24% | +$56K | 0.07% | 210 |
|
|
2016
Q4 | $211K | Buy |
+1,466
| New | +$196K | 0.05% | 249 |
|
Other funds holding ELV
AACR
Parallel Advisors's ELV Position: Q2 2026 in Review
Parallel Advisors increased its Elevance Health (ELV) stake by 21% in Q2 2026, buying an estimated $172K and bringing the position to 2,711 shares worth $1.05M. The position accounts for 0.02% of the portfolio, ranked #507.
Parallel Advisors first reported a position in ELV in Q4 2016 and has held it in 39 quarters since. The position peaked at $2.12M in Q2 2024. 917 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Parallel Advisors held 2,711 shares of Elevance Health worth $1.05M as of Q2 2026.
- Parallel Advisors bought 463 Elevance Health shares in Q2 2026, an estimated $172K.
- Elevance Health made up 0.02% of Parallel Advisors's portfolio in Q2 2026, its #507 holding.
- Parallel Advisors first reported a position in Elevance Health in Q4 2016 and has held it in 39 quarters since.
- Parallel Advisors's Elevance Health position peaked at $2.12M in Q2 2024.
- 917 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.